孟詳喻簡介
姓 名： 孟詳喻
性 別：男
最高學位：博士
職 稱：副教授
職 務：無
mail ： [email protected]
電 話：15827268359
研究方向：干濕結合的疾病機制與轉化研究
個人簡介：
孟詳喻，1990年生，湖北恩施人，土家族，博士，副教授，碩士研究生導師。本碩連讀畢業(yè)于武漢大學（臨床醫(yī)學七年制中法班），期間先后赴法國洛林大學（法國政府獎學金資助）和日本北海道大學訪問學習。博士畢業(yè)于巴黎薩克雷大學（ARWU排名全球12，THE排名全球64），師從膀胱癌領軍學者F. Radvanyi教授，從事膀胱癌腫瘤生物學研究。
中國農(nóng)工民主黨黨員。
省級人才計劃入選者。
任湖北省生物信息學會理事、歐洲腫瘤內(nèi)科學會ESMO會員、全法中國科技工作者協(xié)會會員、亞太生物醫(yī)學免疫學會血液學專委會委員、湖北省醫(yī)學生物免疫學會血液學專委會與青年委員會委員。《臨床內(nèi)科雜志》通訊編委、Phenomics青年編委、iMeta青年編委、Oncology and Translational Medicine青年編委。Advanced Science、British Journal of Psychiatry、 Haematologica、HemaSphere、Journal of Advanced Research、Biomarker Research、MedComm、Clinical and Translational Medicine、Briefings in Bioinformatics、Scientific Data、Journal of Agricultural and Food Chemistry等數(shù)十本SCI期刊審稿人。
以第一/共一/通訊作者在European Urology (IF: 25.3，中科院1區(qū)top；3篇，含1篇封面論文)、Genome Medicine (IF: 10.4，中科院1區(qū)top)、Molecular Cancer (IF: 27.7，中科院1區(qū)top)、Advanced Science (IF: 14.3，中科院1區(qū)top)、Journal of Hematology & Oncology (IF: 29.5，中科院1區(qū)top) 、Theranostics (IF: 12.4，中科院1區(qū)top)、Clinical Chemistry (IF: 7.1，ADLM會刊，醫(yī)學檢驗技術第一刊，中科院小類1區(qū))、Journal for ImmunoTherapy of Cancer (IF: 10.3，中科院1區(qū)top) 、Advanced Healthcare Materials (IF: 10.0) 、Clinical and Translational Medicine (IF: 7.9)等高影響力期刊發(fā)表論文多篇，總引用>1,700，H-index 25。
(Google Scholar，https://scholar.google.com/citations?hl=en&user=JQYDHSkAAAAJ&view_op=list_works&sortby=pubdate)
通曉英（TOEFL iBT, CEFR C1）、法（TEF, CECR B2）、日（JLPT, N1）三門外語。
主持、參與的項目：
1. 湖北省高層次人才項目，楚天英才計劃“楚天學者”，主持；
2. 法國國家健康與醫(yī)學研究院（INSERM）ITMO Cancer AVIESAN Soutien pour la formation à la recherche fondamentale et translationnelle en Cancérologie博士基金項目，21.5萬歐元，主持；
3. 國家自然科學基金青年項目，APOBEC3A驅動膀胱癌發(fā)生發(fā)展的動物模型及其機制研究，30萬元，主持；
4. 國家自然科學基金面上項目，FGFR3突變介導受體過度激活和免疫抑制誘導膀胱癌發(fā)生和治療耐藥的分子機制，49萬元，參與（2/7）；
5. 湖北省自然科學基金青年項目，APOBEC3A驅動膀胱癌發(fā)生和惡性進展的體內(nèi)機制研究，5萬元，主持；
6. 教育部學位與研究生教育發(fā)展中心主題案例項目，利用多組學技術研究土家醫(yī)道地藥材治療阿爾茲海默病的有效成分及其作用機制研究案例，參與（3/6）；
7. 湖北民族大學博士科研啟動基金及省級重點實驗平臺開放課題等多項，主持。
科研教學成果及獎勵：
1. “基于尿液cfDNA的膀胱癌早篩液體活檢關鍵技術及試劑盒研發(fā)”，第五屆全國設備管理與技術創(chuàng)新成果二等獎，2022，中國設備管理協(xié)會.
2. “優(yōu)福能—膀胱癌早篩尖端方案”，2021年中國國際“互聯(lián)網(wǎng)+”大學生創(chuàng)新創(chuàng)業(yè)大賽國家級銅獎，2021，中國國際“互聯(lián)網(wǎng)+”大學生創(chuàng)新創(chuàng)業(yè)大賽組織委員會.
公開發(fā)表論文、教材、專著及課程建設：
論文（*，通訊；#，第一/共一）：
Xiang-Yu Meng#. Cyclic enrichment of urinary exosomes using a MOF-on-MOF-based asymmetric impinging streams chip for bladder cancer diagnosis and prognosis prediction. Adv Healthc Mater. 2025, in press. (IF: 10.0，中科院2區(qū)).
Xiang-Yu Meng#,*. Gene and pathway analysis of genome-wide genetic associations of bladder cancer. Curr Urol. 2025, in press. (IF: 0.9，中科院4區(qū)).
Xiang-Yu Meng*. SysNatMed: rational natural medicine discovery by systems genetics. Front Pharmacol. 2025:1496061 (IF: 4.4, 中科院3區(qū)).
Xiang-Yu Meng*. Cancer liquid biopsies by Oxford Nanopore Technologies sequencing of cell-free DNA: from basic research to clinical applications. Mol Cancer. 2024:265 (IF: 27.7, 中科院1區(qū)top)
Xiang-Yu Meng#. Machine learning-based detection of bladder cancer by urine cfDNA fragmentation hotspots that capture cancer-associated molecular features. Clin Chem. 2024, 70(12):1463-1473 (IF: 7.1, ADLM official journal, 中科院小類1區(qū)).
Xiang-Yu Meng*. Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns. Adv Sci (Weinh). 2024:e2308243 (IF: 14.3, 中科院1區(qū) top).
Xiang-Yu Meng#,*. Sex bias in FGFR3 somatic mutations in bladder cancer. Oncol Trans Med. 2024, 10(5): 252-256 (CSTPCD).
Xiang-Yu Meng*. Single-cell analyses reveal evolution mimicry during the specification of breast cancer subtype. Theranostics. 2024, 14(8):3104-3126 (IF: 12.4, 中科院1 區(qū)top).
Xiang-Yu Meng*. The underexplored role of APOBEC3 enzymes in autoimmune diseases. Rheumatology (Oxford). 2024, 63(6):e166-e167 (IF: 4.7, 中科院2區(qū)).
Xiang-Yu Meng*. Landscape of urine biomarkers for bladder cancer: molecular function, cell-of-origin, and bibliometric trend. Oncol Trans Med. 2024, 10(3):132-142 (CSTPCD).
Xiang-Yu Meng#,*. Tumor mutation burden as a marker for molecularly matched therapy: more evidence needed. Epigenomics. 2023, 15(22):1175-1178 (IF: 3.0, 中科院4區(qū)).
Xiang-Yu Meng#,*. Historical pathogen-driven selection may contribute to contemporary ethnic difference in bladder cancer susceptibility. Bladder Cancer. 2023, 9(3): 211-216 (IF: 1.0, 中科院4區(qū); BCAN official journal)
Xiang-Yu Meng#,*. Comments on “Methylation scores for smoking, alcohol consumption and body mass index and risk of seven types of cancer”. Int J Cancer. 2023, 153(8):1543-1544 (IF: 5.7, 中科院2區(qū)).
Xiang-Yu Meng#,*. NLRC5 germline variants as potential pharmacogenomic markers for immune checkpoint inhibitors. J Immunother Cancer. 2023, 11(6):e007255 (IF: 10.3, 中科院1區(qū) top).
Xiang-Yu Meng*. The potential crosstalk between tumor and plasma cells and its association with clinical outcome and immunotherapy response in bladder cancer. J Transl Med. 2023, 21(1):298 (IF: 6.1, 中科院2 區(qū)top).
Xiang-Yu Meng#,*. “Paradoxical neoantigenic mutations”: not simply a driver vs passenger dualism. Br J Cancer. 2023, 129(1):1-2 (IF: 6.4, 中科院2 區(qū)top).
Xiang-Yu Meng#. FGFR3 mutational activation can induce luminal-like papillary bladder tumor formation and favors a male sex bias. Eur Urol. 2023, 83(1):70-81 (IF: 25.3, 中科院1 區(qū)top).
Xiang-Yu Meng*. Dynamic gene screening enabled identification of a 10-gene panel for early detection and progression assessment of gastric cancer. Comput Struct Biotechnol J. 2022, 21:677-687. (IF: 4.4, 中科院3區(qū))
Xiang-Yu Meng*. Single-cell and spatially resolved analysis uncovers cell heterogeneity of breast cancer. J Hematol Oncol. 2022, 15(1):19 (IF: 29.5, 中科院1區(qū) top).
Xiang-Yu Meng#,*. Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer. Genome Med. 2020, 12(1):85 (IF: 10.4, 中科院1區(qū) top; Feature).
Xiang-Yu Meng*. ΔNp63 drives epithelial differentiation in glioma. Clin Transl Med. 2020, 10(4):e165 (IF: 7.9, 中科院2區(qū) top).
Xiang-Yu Meng#. Estimation and projection about the standardized prevalence of osteoporosis in mainland China. Calcif Tissue Int. 2020, 106(2):131-146 (IF: 3.3, 中科院3區(qū)).
Xiang-Yu Meng#. Reply to Alexander Yang, Vincent L. Cannataro, Jeffrey P. Townsend's Letter to the Editor, re: Ming-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al. APOBEC-mediated Mutagenesis as, a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer. Eur Urol 2019, 76:9-13. Eur Urol. 2020, 77(1):e24-e25 (IF: 25.3, 中科院1區(qū) top).
Xiang-Yu Meng#. APOBEC-mediated mutagenesis as a likely cause of FGFR3 S249C mutation over-representation in bladder cancer. Eur Urol. 2019, 76(1):9-13 (IF: 25.3, 中科院1區(qū) top; Cover).
Xiang-Yu Meng#. The role of COL5A2 in patients with muscle-invasive bladder cancer: a bioinformatics analysis of public datasets involving 787 subjects and 29 cell lines. Front Oncol. 2019, 8:659 (IF: 3.5, 中科院3區(qū)).
Xiang-Yu Meng*. Long-term efficacy of maintenance therapy for multiple myeloma: A quantitative synthesis of 22 randomized controlled trials. Front Pharmacol. 2018, 9:430 (IF: 4.4, 中科院3區(qū)).
Xiang-Yu Meng*. Bortezomib, thalidomide, and dexamethasone (VTD) induction results in better overall survival than adriamycin, thalidomide, and dexamethasone (ATD) induction in previously untreated myeloma patients eligible for transplants. Acta Haematol. 2017, 137(4):207-208 (IF: 1.7, 中科院4區(qū)).
Xiang-Yu Meng*. La relation entre la récurrence de la tumeur et les polymorphismes génétiques de hGPX1 et NRAMP1 chez les patients atteints du cancer superficiel de la vessie: une méta-analyse. Pan Afr Med J. 2017, 27: 270 (in French).
Xiang-Yu Meng*. Baicalein suppresses the proliferation of acute T-lymphoblastic leukemia Jurkat cells by inhibiting the Wnt/β-catenin signaling. Ann Hematol. 2016, 95(11):1787-93 (IF: 3, 中科院3區(qū)).
教材及專著：
《DK人體百科（涂色版）》，2019，北京科學技術出版社，主譯
《人體筋膜系統(tǒng)功能學圖譜》，2017，北京科學技術出版社，副主譯
《應用STATA做Meta分析》，2016，中國協(xié)和醫(yī)科大學出版社，編者
《循證臨床實踐指南的研發(fā)與評價》，2016，中國協(xié)和醫(yī)科大學出版社，編者
《R與Meta分析》，2016，軍事醫(yī)學科學出版社，編者